过去一年中添加的文章，按日期排序
Covid-19 in patients with haematological malignancies
H Warda, K Skórka… - Acta Haematologica …, 2024 - journals.viamedica.pl
115 天前 - … of COVID-19 in patients with … efficacy of vaccines against COVID-19, and
vaccine-drug interactions specifically in cohorts of patients with chronic lymphocytic leukemia …
vaccine-drug interactions specifically in cohorts of patients with chronic lymphocytic leukemia …
… prophylaxis with monoclonal-antibody tixagevimab-cilgavimab against emerging SARS-CoV-2 resistant variants in patients with chronic lymphocytic leukemia
O Benjamini, T Tadmor, A Avigdor, R Gershon… - Acta …, 2024 - karger.com
117 天前 - … to COVID-19 vaccine for immunocompromised and those with insufficient immune
response, among them patients … titers and neutralization activity of COVID-19 wild-type (WT), …
response, among them patients … titers and neutralization activity of COVID-19 wild-type (WT), …
Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies
P Reimann, V Petzer, A Mündlein, B Hartmann… - Annals of …, 2024 - Springer
127 天前 - … Patients with chronic lymphocytic leukaemia (CLL)/lymphoma were at highest risk
of a COVID-19 … , we report the efficacy (by rate of COVID-19 breakthrough infections and …
of a COVID-19 … , we report the efficacy (by rate of COVID-19 breakthrough infections and …
Hybrid immunity to SARS‐CoV‐2 in patients with chronic lymphocytic leukemia
SC Mellinghoff, S Robrecht, R Sprute… - European Journal of …, 2024 - Wiley Online Library
154 天前 - … CLL patients after fourth COVID-19 vaccination combined … Patients with prior
vaccination failure now show a specific … explore the duration and effectiveness of hybrid immunity …
vaccination failure now show a specific … explore the duration and effectiveness of hybrid immunity …
The GLOW trial in chronic lymphocytic leukaemia–Authors' reply
CU Niemann, AP Kater - The Lancet Oncology, 2024 - thelancet.com
160 天前 - … for frail patients with chronic lymphocytic leukaemia (CLL), and why more patient-related …
Last, cost-effectiveness studies are indeed important and should be independently …
Last, cost-effectiveness studies are indeed important and should be independently …
Efficacy of COVID-19 Vaccines in Patients with Hematological Malignancy Compared to Healthy Controls: A Systematic Review and Meta-analysis
AD Barshan, ELA Matsumoto-Takahashi - JMA journal, 2024 - jstage.jst.go.jp
186 天前 - … Multiple myeloma, chronic lymphocytic leukemia, and lymphoma were the cancers
of … BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. …
of … BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. …
Efficacy and Tolerance of the BNT162b2 Vaccine in Children with Acute Leukemia and Their Siblings: Results of the Phase I-II Pacific Trial
FA Laurent, A Ouedrani, P Jatteau, M Strullu… - Blood, 2023 - Elsevier
222 天前 - Introduction: Severe forms of COVID-19 caused by SARS-CoV-2 have been observed
in children with hematological malignancies. Occurrence of the infection during treatment …
in children with hematological malignancies. Occurrence of the infection during treatment …
Epic: A Second Interim Analysis of the Non-Interventional, Observational Multi-Centre Cohort Study of Patients with Chronic Lymphocytic Leukaemia Treated with First …
R Walewska, N Martinez-Calle, J Hickey, H Harding… - Blood, 2023 - Elsevier
222 天前 - … However, real-world data detailing the safety and effectiveness of first-line acalabrutinib
… COVID-19 vaccination and biannual boosters is offered to all patients with CLL as per …
… COVID-19 vaccination and biannual boosters is offered to all patients with CLL as per …
COVID-19 Related Mortality Does Not Correlate with Vaccine Availability in Leukemia Patients: 2020-2023 Analysis in the United States
T Varughese, M Kabat, E Zolotov, J Koprivnikar - Blood, 2023 - Elsevier
222 天前 - … We included respective ICD codes: C91 lymphoid leukemia, C92 myeloid leukemia,
… efficacy of the COVID-19 vaccine in immunocompromised patients. One study showed …
… efficacy of the COVID-19 vaccine in immunocompromised patients. One study showed …
Efficacy and Safety of Tixagevimab-Cilgavimab (Evusheld or AZD7442) As Pre-Exposure Prophylaxis for COVID-19 Among Allogeneic Hematopoietic Stem Cell …
Q Do, W Bahaj, N Chandler, JH Chao, RVB Emmons… - Blood, 2023 - Elsevier
222 天前 - … patients are at higher risk of COVID-19, and may fail to mount a robust immune
response to vaccination. In … acute myeloid leukemia (47.9%), acute lymphocytic leukemia (6.3%), …
response to vaccination. In … acute myeloid leukemia (47.9%), acute lymphocytic leukemia (6.3%), …